Back to Search
Start Over
Therapeutic innovations in breast cancer
- Source :
- La Presse Médicale, La Presse Médicale, Elsevier Masson, 2019, 48, pp.1131-1137. ⟨10.1016/j.lpm.2019.04.005⟩
- Publication Year :
- 2019
- Publisher :
- HAL CCSD, 2019.
-
Abstract
- Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting. New antibodies drug conjugates for HER2+ and TNBC. Targeting DNA damage and synthetic lethality strategies with PARP inhibitors for breast cancer patients harboring BRCA mutation. Immunotherapies in 1st line metastatic setting of TNBC.
- Subjects :
- Drug
Immunoconjugates
DNA damage
media_common.quotation_subject
[SDV]Life Sciences [q-bio]
Breast Neoplasms
Synthetic lethality
Poly(ADP-ribose) Polymerase Inhibitors
03 medical and health sciences
0302 clinical medicine
Breast cancer
Cyclin-dependent kinase
medicine
Humans
030212 general & internal medicine
skin and connective tissue diseases
Protein Kinase Inhibitors
media_common
Randomized Controlled Trials as Topic
biology
business.industry
BRCA mutation
Endocrine therapy
Cyclin-Dependent Kinase 4
General Medicine
Cyclin-Dependent Kinase 6
medicine.disease
3. Good health
030220 oncology & carcinogenesis
biology.protein
Cancer research
Female
Immunotherapy
Antibody
business
Subjects
Details
- Language :
- English
- ISSN :
- 07554982 and 22130276
- Database :
- OpenAIRE
- Journal :
- La Presse Médicale, La Presse Médicale, Elsevier Masson, 2019, 48, pp.1131-1137. ⟨10.1016/j.lpm.2019.04.005⟩
- Accession number :
- edsair.doi.dedup.....08ce715272389e78959c6851c6e6e292